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The recent concise commentary by Avindra Nath [1] discusses the report by one of us (Tzeng 
et al. [2]), in a recent issue of Neurotherapeutics that addressed a potential protective role for 
antiviral therapy (AVT) in Alzheimer's disease (AD). In this  retrospective study employing 
the Taiwan National Health Insurance Database, Tzeng et al. reported that short-term AVT of 
patients with overt herpes virus infections was followed by a long-term reduction in the 
subsequent incidence of AD over the following decade ([2]; discussed in [3]). In his 
commentary Dr Nath queries the results of this study ('alternative fact'), and concludes that it 
might merely be safe to treat 'patients who develop herpes virus infections with appropriate 
antiviral drugs' [1], a proposal wisely consistent with current practice. Although the 
commentary makes interesting points, other issues appear to be misconstrued and warrant 
urgent rectification, which we offer in the hope of clarifying the situation. 
 
Dr Nath is correct is in pointing out that the Tzeng et al. study is retrospective in nature, and 
thus raises issues concerning proper diagnosis in the absence of neuroimaging or postmortem 
pathological analysis. However, the Taiwan database employs an accredited diagnostic 
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instrument (International Classification of Disease, Ninth Revision, Clinical Modification: 
ICD-9-CM), and thus is unlikely to be a major confounding factor.  
 
Dr Nath further points out that there was also a lack of identification of genetic risk factors. 
We agree that this latter is extremely important because diverse immune-related genes are 
associated both with infection and AD development. Centrally, ε4 alleles of the APOE gene 
are susceptibility factors not only for AD but also for several infectious diseases. The ε4 allele 
is known to increase susceptibility to infection damage by, among others, herpes simplex 
virus type 1 (HSV1) [4,5], HSV2 [6,7], Chlamydia pneumoniae [8], Chlamydia-associated 
arthritis [9], and HIV [10]. Some other AD risk alleles are also known to predispose to 
infectious disease; for example, genetic variants in PILRA, a receptor for HSV-1 glycoprotein 
B (that governs HSV-1 viral entry into cells), are associated with AD [11]. Therefore, the 
population studied in the Tzeng et al. report (acute HSV1/2 infection) was likely to have been 
enriched in AD risk alleles, including APOE ε4, and thus may have been inherently at 
increased risk of later AD development. No genomic studies were performed on patients in 
the Tzeng et al. study, and although we do not believe that this detracts from the potential 
protective role of AVT reported by Tzeng et al., we agree (as discussed further below) that 
such genetic predisposition could potentially underlie positive associations (possibly 
circumstantial) between AD and different infectious conditions including herpes zoster 
ophthalmicus [12], varicella zoster [13], peridontal disease [14-16], Borrelia burgdorferi [17], 
and Chlamydophila pneumoniae [18]. 
 
We highlight this genetic factor because it must be carefully borne in mind when considering 
the next caveat listed by Nath [1] – 'selection bias for treatment'. The Tzeng et al. [2] study 
compared patients with acute HSV-induced lesions (predominantly orolabial and genital) who 
received AVT versus those who were not treated. It could be argued that the patients who 
received AVT were likely to have suffered from more severe lesions than those who went 
untreated. In consequence, the AVT group (likely with more serious lesions) may have been 
biased towards inclusion of individuals with a genetic predisposition to AD.  
 
Our central argument, therefore, is that the AVT group might have been at increased (rather 
than decreased) risk of later AD development. By contrast, it was precisely the AVT group 
that showed a dramatic reduction in later AD development. The potential treatment bias cited 
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by Nath argues in exactly the reverse direction. Thus, it is even more remarkable that their 
treatment with AVT apparently prevented most (ca 90%) cases of AD development in the 
decade that followed. Treatment bias, if it exists, would therefore entirely support (rather than 
challenge) the reality of the preventive effect of AVT.  
 
An additional major issue in Nath's commentary also calls for clarification. He states that 'one 
would have to postulate that the virus establishes a chronic or persistent infection in the brain 
to cause cognitive deficits. However, given what we know about these viruses, this would be 
highly unlikely' [1]. We must point out that this is not correct. 
 
Seropositivity for HSV1 and 2 increases over our lifetime: HSV infection is generally 
acquired during postnatal life, and HSV seropositivity increases with age in the USA [19] and 
Europe [20], as well as in Taiwan [21], and by age 50 years the majority of the population 
harbors HSV1 and/or HSV2 (often in addition to other herpes viruses such as 
cytomegalovirus and Epstein–Barr virus). Following primary infection (generally of epithelial 
cells) that can be symptomatic or asymptomatic, HSV1 enters a silent (latent) state (reviewed 
in [22,23]) principally in neurons in peripheral ganglia and other tissues, from where it can 
intermittently reactivate. In the nervous system, HSV1 can latently persist for decades, 
notably in the trigeminal ganglia [24-27], but can invade many brain regions. HSV1 receptors 
are most abundantly expressed in the hippocampus [28], a site of early degeneration in AD. 
Indeed, HSV1 DNA can be detected in several brain regions including the hippocampus, both 
of control individuals and AD patients [29,30], but levels are upregulated in AD brain, as 
recently confirmed for HSV1/2 as well as for human herpes viruses (HHV) 6 and 7 [31]. The 
pathological signature of AD, Abeta protein, is induced by HSV1 infection [32] and is 
increasingly recognized as an antimicrobial factor ([33], reviewed in [34]) that exerts potent 
anti-HSV1 effects [35,36]. Although de novo brain invasion with HHV following disease 
onset cannot be ruled out [37], this is not the case for HSV1 that is widely detected in both 
AD and control brain tissue [30,31,38]. There are also suggestions that a declining immune 
system in the elderly might predispose to virus reactivation: the immune system undergoes 
systemic changes over a lifetime (e.g., [39]) and reactivation of HSV1 has been reported to 
take place as a function of age [40,41]. Diverse types of evidence for reactivation of HSV1 in 
human brain have been described in detail [42]. The available data thus manifestly rebut 
Nath's view that 'a chronic or persistent infection in the brain ... would be highly unlikely.'  
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This indirectly answers the question raised by Nath – 'why would herpes virus infection in the 
genitalia or lips lead to dementia' – in short, it may not (or not directly). Instead, reactivation 
of epithelial HSV1 might be accompanied (particularly in genetically predisposed individuals) 
by reactivation in other tissues including the brain, that then initiates the lesions that, over the 
following decades, culminate in clinical AD. Alternatively (or in addition), in cases of de 
novo orogenital infections, increased peripheral virus load and/or inflammation might increase 
the likelihood that virus enters the brain [3]. 
 
A final issue raised by Nath concerns the apparent non-specificity of the association between 
infection, AVT, and AD. He very properly highlights that several types of infectious agent 
have been associated with AD, and that minor infections of the elderly can be associated with 
cognitive decline.  However, this non-specificity does not extend to AVT. Current AVT 
compounds used to combat herpes viruses are highly specific for this class of viruses: these 
agents (e.g., acyclovir, ganciclovir, penciclovir, etc.) are nucleoside analogs that require 
phosphorylation by the viral thymidine kinase enzyme (and recognition of the ensuing 
triphosphates by viral DNA polymerases) for inhibition of virus proliferation. These 
compounds are poorly recognized by the corresponding enzymes of other virus classes and 
display much less or no antiviral activity against them (e.g., vaccinia virus or even veterinary 
herpes viruses) [43,44]. There is evidence that ganciclovir does have inhibitory activity 
against adenovirus [48], but this is not the first-line antiherpetic drug, and others in the class 
are ineffective against adenoviruses. There have been suggestions that acyclovir might have 
some activity against HIV by targeting the reverse transcriptase enzyme [45], but virus-
inhibitory concentrations are 10–100-fold higher than for herpes viruses, and acyclovir failed 
to prevent HIV transmission [46]. Therefore, although inhibition of a so far unidentified virus 
class cannot yet be ruled out, it is most likely that the protective efficacy of AVT observed by 
Tzeng et al. is through selective targeting of one or more herpes viruses (although the precise 
virus type remains to be established). 
 
To conclude, Dr Nath has clearly not overlooked the potential implications of the Tzeng et al. 
report. However, we argue that, far from representing 'alternative fact', the findings of the 
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